Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN4242,13-1,53
Msft0,07
Nokia3,56553,57451,04
IBM-1,97
Daimler AG47,8847,895-1,46
PFE-1,09
21.10.2020 22:30:00
Indexy online
AD Index online
select
AD Index online
 

  • 21.10.2020 22:00:00
Prothena Corporation PLC, Ordinary, Consolidated Issue listed on NASDAQ Global Market (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
11,95 6,13 0,69 814 702
After-hours21.10.2020 22:30:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
11,95 - - 6,13 0,69
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 21.10.2020
Popis společnosti
Obecné informace
Název společnostiProthena Corporation PLC
TickerPRTA
Kmenové akcie:Ordinary Shares
RICPRTA.O
ISINIE00B91XRN20
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 51
Akcie v oběhu k 31.07.2020 39 911 413
Počet akcionářů k 31.12.2019 1 147
MěnaUSD
Kontaktní informace
UliceDublin 1, 25-28 North Wall Quay
MěstoDUBLIN
PSČA96 T927
ZeměIreland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon35 312 362 500
Fax35319023510

Business Summary: Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Prothena Corporation PLC revenues decreased 5% to $336K. Net loss increased 36% to $49.9M. Revenues reflect Collaboration revenue decrease of 19% to $286K. Higher net loss reflects Research and development - gross increase of 52% to $28.4M (expense), Interest income decrease of 71% to $1.3M (income), General and administrative - gross increase of 14% to $12.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 21.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardLars Ekman70
President, Chief Executive Officer, DirectorGene Kinney5130.09.2016
Chief Financial Officer, Chief Operating OfficerTran Nguyen4621.06.2018
Chief Accounting Officer, ControllerKarin Walker5620.05.2013
Chief Scientific OfficerWagner Zago4712.06.201712.06.2017
Chief Regulatory OfficerCarol Karp6715.12.201615.12.2016
Chief Business OfficerBrandon Smith4503.03.202003.03.2020
Chief Development OfficerRadhika Tripuraneni4001.01.2018
Chief Legal Officer and Company SecretaryMichael Malecek54